Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3074)
All Articles published online
|
Oct 21, 2005 (publication date) through Nov 27, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Zeng L, Cao J, Zhang X. Expression of serine protease SNC19/matriptase and its inhibitor hepatocyte growth factor activator inhibitor type 1 in normal and malignant tissues of gastrointestinal tract. World J Gastroenterol 2005; 11(39): 6202-6207 [PMID: 16273651 DOI: 10.3748/wjg.v11.i39.6202] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v11/i39/6202.htm |
| Number | Citing Articles |
| 1 |
Fausto A. Varela, Thomas E. Hyland, Karin List. Extracellular Targeting of Cell Signaling in Cancer. 2018; : 91 doi: 10.1002/9781119300229.ch4
|
| 2 |
Fang Ye, Shuang Chen, Xingxing Liu, Xiaohong Ye, Keqi Wang, Zhiping Zeng, Ying Su, Xiao‐kun Zhang, Hu Zhou. 3‐Cl‐AHPC inhibits pro‐HGF maturation by inducing matriptase/HAI‐1 complex formation. Journal of Cellular and Molecular Medicine 2019; 23(1): 155 doi: 10.1111/jcmm.13900
|
| 3 |
Christian Parr, Wen G. Jiang. Metastasis of Breast Cancer. Cancer Metastasis – Biology and Treatment 2007; 11: 171 doi: 10.1007/978-1-4020-5867-7_9
|
| 4 |
|
| 5 |
QIAOLI ZHENG, HAIJIAN WU, JIANG CAO, JINGJIA YE. Hepatocyte growth factor activator inhibitor type-1 in cancer: Advances and perspectives (Review). Molecular Medicine Reports 2014; 10(6): 2779 doi: 10.3892/mmr.2014.2628
|
| 6 |
Xiaoxiao Du, Lingyan Wu, Muhammad Saif Ur Rahman, Xiaodong Teng, Lisong Teng, Jingjia Ye, Jiang Cao. Promoter Hypomethylation Is Responsible for Upregulated Expression of HAI-1 in Hepatocellular Carcinoma. Disease Markers 2019; 2019: 1 doi: 10.1155/2019/9175215
|
| 7 |
Jingjia Ye, Makiko Kawaguchi, Yukihiro Haruyama, Ai Kanemaru, Tsuyoshi Fukushima, Koji Yamamoto, Chen‐Yong Lin, Hiroaki Kataoka. Loss of hepatocyte growth factor activator inhibitor type 1 participates in metastatic spreading of human pancreatic cancer cells in a mouse orthotopic transplantation model. Cancer Science 2014; 105(1): 44 doi: 10.1111/cas.12306
|
| 8 |
Makiko Kawaguchi, Hiroaki Kataoka. Mechanisms of Hepatocyte Growth Factor Activation in Cancer Tissues. Cancers 2014; 6(4): 1890 doi: 10.3390/cancers6041890
|
| 9 |
Andrew S. Murray, Fausto A. Varela, Karin List. Type II transmembrane serine proteases as potential targets for cancer therapy. Biological Chemistry 2016; 397(9): 815 doi: 10.1515/hsz-2016-0131
|
| 10 |
Benjamin Owusu, Robert Galemmo, James Janetka, Lidija Klampfer. Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment. Cancers 2017; 9(4): 35 doi: 10.3390/cancers9040035
|
| 11 |
Benjamin Y. Owusu, Shantasia Thomas, Phanindra Venukadasula, Zhenfu Han, James W. Janetka, Robert A. Galemmo, Lidija Klampfer. Targeting the tumor-promoting microenvironment in MET-amplified NSCLC cells with a novel inhibitor of pro-HGF activation. Oncotarget 2017; 8(38): 63014 doi: 10.18632/oncotarget.18260
|
| 12 |
Kuniyo Inouye, Satoshi Tsuzuki, Makoto Yasumoto, Kenji Kojima, Seiya Mochida, Tohru Fushiki. Identification of the Matriptase Second CUB Domain as the Secondary Site for Interaction with Hepatocyte Growth Factor Activator Inhibitor Type-1*. Journal of Biological Chemistry 2010; 285(43): 33394 doi: 10.1074/jbc.M110.115816
|
| 13 |
K. Ji, B.F. Sloane. Encyclopedia of Cell Biology. 2016; : 753 doi: 10.1016/B978-0-12-394447-4.10085-9
|
| 14 |
Hongmok Kwon, Hyunsoo Ha, Hayoung Jeon, Jaebong Jang, Sang-Hyun Son, Kiho Lee, Song-Kyu Park, Youngjoo Byun. Structure-activity relationship studies of dipeptide-based hepsin inhibitors with Arg bioisosteres. Bioorganic Chemistry 2021; 107: 104521 doi: 10.1016/j.bioorg.2020.104521
|
| 15 |
Ping Hu, Le Shang, Jincan Chen, Xuzheng Chen, Chun Chen, Wanjin Hong, Mingdong Huang, Peng Xu, Zhuo Chen. A nanometer-sized protease inhibitor for precise cancer diagnosis and treatment. Journal of Materials Chemistry B 2020; 8(3): 504 doi: 10.1039/C9TB02081K
|
| 16 |
Lotte K Vogel, Mona Sæbø, Camilla F Skjelbred, Kathrine Abell, Esben DK Pedersen, Ulla Vogel, Elin H Kure. The ratio of Matriptase/HAI-1mRNA is higher in colorectal cancer adenomas and carcinomas than corresponding tissue from control individuals. BMC Cancer 2006; 6(1) doi: 10.1186/1471-2407-6-176
|
| 17 |
Keiichiro Nakamura, Atsushi Hongo, Junichi Kodama, Yuji Hiramatsu. The role of hepatocyte growth factor activator inhibitor (HAI)‐1 and HAI‐2 in endometrial cancer. International Journal of Cancer 2011; 128(11): 2613 doi: 10.1002/ijc.25606
|
| 18 |
Mei Ji, Shunshuang Li, Ya Xie, Zhao Zhao, Weizhong Chang, Yue Li, Xinghan Cheng, Zhuo Wang. Expression and prognostic value of matriptase in ovarian serous adenocarcinoma. Oncology Letters 2017; 13(3): 1741 doi: 10.3892/ol.2017.5600
|
| 19 |
Sauryang Kim, Jae Woong Yang, Chungho Kim, Moon Gyo Kim. Impact of suppression of tumorigenicity 14 (ST14)/serine protease 14 (Prss14) expression analysis on the prognosis and management of estrogen receptor negative breast cancer. Oncotarget 2016; 7(23): 34643 doi: 10.18632/oncotarget.9155
|
| 20 |
Carolyn V. Ustach, Wei Huang, M. Katie Conley-LaComb, Chen-Yong Lin, Mingxin Che, Judith Abrams, Hyeong-Reh Choi Kim. A Novel Signaling Axis of Matriptase/PDGF-D/β-PDGFR in Human Prostate Cancer. Cancer Research 2010; 70(23): 9631 doi: 10.1158/0008-5472.CAN-10-0511
|
| 21 |
Karin List, Thomas H. Bugge, Roman Szabo. Matriptase: Potent Proteolysis on the Cell Surface. Molecular Medicine 2006; 12(1-3): 1 doi: 10.2119/2006-00022.List
|
| 22 |
Lidija Klampfer, Benjamin Yaw Owusu. Extracellular Targeting of Cell Signaling in Cancer. 2018; : 45 doi: 10.1002/9781119300229.ch2
|
| 23 |
Topi A. Tervonen, Johanna I. Partanen, Sirkku T. Saarikoski, Mikko Myllynen, Elsa Marques, Katriina Paasonen, Anu Moilanen, Gerd Wohlfahrt, Panu E. Kovanen, Juha Klefstrom. . Advances in Cancer Research 2011; 111: 97 doi: 10.1016/B978-0-12-385524-4.00003-9
|
| 24 |
K U Sales, S Friis, L Abusleme, N M Moutsopoulos, T H Bugge. Matriptase promotes inflammatory cell accumulation and progression of established epidermal tumors. Oncogene 2015; 34(35): 4664 doi: 10.1038/onc.2014.391
|
| 25 |
Benjamin Y. Owusu, Namita Bansal, Phanindra K.M. Venukadasula, Larry J. Ross, Troy E. Messick, Sanjay Goel, Robert A. Galemmo, Lidija Klampfer. Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling. Oncotarget 2016; 7(20): 29492 doi: 10.18632/oncotarget.8785
|
| 26 |
Lauren M. Tanabe, Karin List. The role of type II transmembrane serine protease‐mediated signaling in cancer. The FEBS Journal 2017; 284(10): 1421 doi: 10.1111/febs.13971
|
| 27 |
Tao Ning, Haiyang Zhang, Xinyi Wang, Shuang Li, Le Zhang, Ting Deng, Likun Zhou, Xia Wang, Rui Liu, Ming Bai, Shaohua Ge, Hongli Li, Dingzhi Huang, Guoguang Ying, Yi Ba. miR-221 and miR-222 synergistically regulate hepatocyte growth factor activator inhibitor type 1 to promote cell proliferation and migration in gastric cancer. Tumor Biology 2017; 39(6): 101042831770163 doi: 10.1177/1010428317701636
|
| 28 |
Toni M. Antalis, Thomas H. Bugge, Qingyu Wu. Proteases in Health and Disease. Progress in Molecular Biology and Translational Science 2011; 99: 1 doi: 10.1016/B978-0-12-385504-6.00001-4
|
| 29 |
Newton J. Hurst, Abdo J. Najy, Carolyn V. Ustach, Lisa Movilla, Hyeong-Reh Choi Kim. Platelet-derived growth factor-C (PDGF-C) activation by serine proteases: implications for breast cancer progression. Biochemical Journal 2012; 441(3): 909 doi: 10.1042/BJ20111020
|
| 30 |
Phanindra K. M. Venukadasula, Benjamin Y. Owusu, Namita Bansal, Larry J. Ross, Judith V. Hobrath, Donghui Bao, Jackie W. Truss, Murray Stackhouse, Troy E. Messick, Lidija Klampfer, Robert A. Galemmo. Design and Synthesis of Nonpeptide Inhibitors of Hepatocyte Growth Factor Activation. ACS Medicinal Chemistry Letters 2016; 7(2): 177 doi: 10.1021/acsmedchemlett.5b00357
|
| 31 |
Joanna Selzer-Plon, Jette Bornholdt, Stine Friis, Hanne C Bisgaard, Inger MB Lothe, Kjell M Tveit, Elin H Kure, Ulla Vogel, Lotte K Vogel. Expression of prostasin and its inhibitors during colorectal cancer carcinogenesis. BMC Cancer 2009; 9(1) doi: 10.1186/1471-2407-9-201
|
| 32 |
Sander P.J. Joosten, Marcel Spaargaren, Hans Clevers, Steven T. Pals. Hepatocyte growth factor/MET and CD44 in colorectal cancer: partners in tumorigenesis and therapy resistance. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2020; 1874(2): 188437 doi: 10.1016/j.bbcan.2020.188437
|
| 33 |
Tsuyoshi Fukushima, Makiko Kawaguchi, Masatoshi Yamasaki, Hiroyuki Tanaka, Kenji Yorita, Hiroaki Kataoka. Hepatocyte growth factor activator inhibitor type 1 suppresses metastatic pulmonary colonization of pancreatic carcinoma cells. Cancer Science 2011; 102(2): 407 doi: 10.1111/j.1349-7006.2010.01808.x
|
| 34 |
Aaron C. Mitchell, Deepti Kannan, Sean A. Hunter, R. Andres Parra Sperberg, Cheryl H. Chang, Jennifer R. Cochran. Engineering a potent inhibitor of matriptase from the natural hepatocyte growth factor activator inhibitor type-1 (HAI-1) protein. Journal of Biological Chemistry 2018; 293(14): 4969 doi: 10.1074/jbc.M117.815142
|
| 35 |
Vishnu C Damalanka, James W Janetka. Recent Progress on Inhibitors of the Type II Transmembrane Serine proteases, hepsin, Matriptase and matriptase-2. Future Medicinal Chemistry 2019; 11(7): 743 doi: 10.4155/fmc-2018-0446
|
| 36 |
Kuniyo Inouye, Makoto Yasumoto, Satoshi Tsuzuki, Seiya Mochida, Tohru Fushiki. The optimal activity of a pseudozymogen form of recombinant matriptase under the mildly acidic pH and low ionic strength conditions. The Journal of Biochemistry 2010; 147(4): 485 doi: 10.1093/jb/mvp190
|
| 37 |
Kyungmin Ji, Bonnie F. Sloane. Encyclopedia of Cell Biology. 2023; : 712 doi: 10.1016/B978-0-12-821618-7.00236-4
|